EUVIMEDEUVIMED entdecken
Open Access

Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection

Michael J Ricciardi iD, Lauren N Rust iD, Nuria Pedreño-Lopez iD, Sofiya Yusova iD, Sreya Biswas iD, Gabriela M Webb, Lucas Gonzalez-Nieto iD, Thomas B Voigt iD, Johan J Louw iD, Fernanda D Laurino iD, John R DiBello, Hans-Peter Raué und 21 weitere

Science Translational Medicine · 29.03.2023 · 15 (689)

DOI: 10.1126/scitranslmed.ade5795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 29.03.2023. Verfasst von Michael J Ricciardi und 32 weiteren Autor:innen. Beteiligte Einrichtung: Mabloc LLC, 725 21st St. NW, Suite 301, Washington, DC 20052, USA. Hauptthemen laut MEDLINE: Yellow Fever Vaccine, Yellow Fever. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Yellow fever virus (YFV) is a reemerging global health threat, driven by several factors, including increased spread of the mosquito vector and rapid urbanization. Although a prophylactic vaccine exists, vaccine hesitancy, supply deficits, and distribution difficulties leave specific populations at risk of severe YFV disease, as evidenced by recent outbreaks in South America. To establish a treatment for patients with severe YFV infection, we tested 37 YFV-specific monoclonal antibodies isolated from vaccinated humans and identified two capable of potently neutralizing multiple pathogenic primary YFV isolates. Using both hamster and nonhuman primate models of lethal YFV infection, we demonstrate that a single administration of either of these two potently neutralizing antibodies during acute infection fully controlled viremia and prevented severe disease and death in treated animals. Given the potential severity of YFV-induced disease, our results show that these antibodies could be effective in saving lives and fill a much-needed void in managing YFV cases during outbreaks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Yellow Fever VaccineYellow FeverCricetinaeAnimalsHumansYellow fever virusAntibodies, NeutralizingAntibodies, ViralAntibodies, Monoclonal

Substanzen

Antibodies, NeutralizingYellow Fever VaccineAntibodies, ViralAntibodies, Monoclonal

Autor:innen und Institutionen

  • Mabloc LLC, 725 21st St. NW, Suite 301, Washington, DC 20052, USA.
  • George Washington University, 2121 I St. NW, Washington, DC 20052, USA.
  • Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, OR 97006, USA.
  • IrsiCaixa AIDS Research Institute, Ctra. del Canyet SN, Badalona 08916, Barcelona, Spain.
  • Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
  • Oregon National Primate Research Center, Oregon Health and Science University, Beaverton, OR 97006, USA.

ORCID-Profile: Michael J Ricciardi, Lauren N Rust, Nuria Pedreño-Lopez, Sofiya Yusova, Sreya Biswas, Lucas Gonzalez-Nieto, Thomas B Voigt, Johan J Louw, Fernanda D Laurino, Samantha Uttke, Lidiane M S Raphael, Aaron Yrizarry-Medina, Brandon C Rosen, Rebecca Agnor, Lina Gao, Caralyn Labriola, Michael Axthelm, Jeremy Smedley, Justin G Julander, Myrna C Bonaldo, Laura M Walker, Ilhem Messaoudi, Mark K Slifka, Dennis R Burton, Esper G Kallas, Jonah B Sacha, David I Watkins, Benjamin J Burwitz

Förderung

  • NIAID NIH HHS
  • NIH HHS

Zitieren

APA

Ricciardi, M. J., Rust, L. N., Pedreño-Lopez, N., Yusova, S., Biswas, S., Webb, G. M., Gonzalez-Nieto, L., Voigt, T. B., Louw, J. J., Laurino, F. D., DiBello, J. R., Raué, H. P., Barber-Axthelm, A. M., Chun, K., Uttke, S., Raphael, L. M. S., Yrizarry-Medina, A., Rosen, B. C., Agnor, R., …, & Burwitz, B. J. (2023). Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Science Translational Medicine, 15(689). https://doi.org/10.1126/scitranslmed.ade5795

Vancouver

Ricciardi MJ, Rust LN, Pedreño-Lopez N, Yusova S, Biswas S, Webb GM, et al. Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection. Science Translational Medicine. 2023;15(689). doi:10.1126/scitranslmed.ade5795

BibTeX
@article{Ricciardi2023,
  author = {Ricciardi, Michael J and Rust, Lauren N and Pedreño-Lopez, Nuria and Yusova, Sofiya and Biswas, Sreya and Webb, Gabriela M and Gonzalez-Nieto, Lucas and Voigt, Thomas B and Louw, Johan J and Laurino, Fernanda D and DiBello, John R and Raué, Hans-Peter and Barber-Axthelm, Aaron M and Chun, Kimberly and Uttke, Samantha and Raphael, Lidiane M S and Yrizarry-Medina, Aaron and Rosen, Brandon C and Agnor, Rebecca and Gao, Lina and Labriola, Caralyn and Axthelm, Michael and Smedley, Jeremy and Julander, Justin G and Bonaldo, Myrna C and Walker, Laura M and Messaoudi, Ilhem and Slifka, Mark K and Burton, Dennis R and Kallas, Esper G and Sacha, Jonah B and Watkins, David I and Burwitz, Benjamin J},
  title = {Therapeutic neutralizing monoclonal antibody administration protects against lethal yellow fever virus infection},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {689},
  doi = {10.1126/scitranslmed.ade5795}
}
Kostenlos starten →